From silos to shared plans: A complex intervention development and specification study of the GAPA digital infrastructure for cross-organisational oralhealth care planning in home care - Summary - DentalSpire
To develop and specify a cross-organisational digital platform for shared oral health care planning between municipal home care and public dental services.
Approach:
Design: Multimethod intervention development study guided by the updated Medical Research Council framework, co-design, and integrated knowledge translation.
Development: Across five cycles from January 2022 to February 2026, work progressed from needs assessment and paper-based workflow modelling through iterative prototyping to a high-fidelity platform specification.
Requirements: The proposed shared planning environment included structured oral health assessments, preferences and consent, agreed actions, responsible actors, follow-up dates, and declined recommendations.
Key Findings:
The development work specified a platform intended to make oral health assessments, care plans, responsibilities, and follow-up visible to authorised municipal and dental-service users.
The programme theory proposed that shared information could support a common understanding, clearer task allocation, and traceable follow-up.
The platform requirements included the Revised Oral Assessment Guide, conditional assessment of oral hygiene ability, and visibility of unresolved oral health needs.
Interpretation:
The study translated the GAPA programme theory into requirements for a shared digital planning infrastructure. It reports development and specification, not evidence of effectiveness.
Limitations:
The study did not evaluate implementation outcomes or effectiveness.
No patient outcome data were included.
Conclusion:
The work produced a high-fidelity platform specification intended for later feasibility, implementation, and outcome evaluation.
Antibody-drug conjugates (ADCs) have become an increasingly important part of treatment for several advanced cancers, pairing a tumor-targeting antibody with a cytotoxic payload.
